Dr. Lal Path Labs publishes notice for unclaimed equity shares for FY 2018-19
Dr. Lal Path Labs Ltd. is issuing a notice to equity shareholders regarding unclaimed shares from FY 2018-19, which are to be transferred to the IEPF. Individual notices have been sent, and details are on the company's website. The advertisement was published on March 19, 2026.
This is a standard regulatory compliance activity related to unclaimed dividends and does not directly impact the company's operations or financial performance.
The announcement is a routine regulatory filing regarding unclaimed shares and does not contain any positive or negative financial or business performance information.
Dr. Lal Path Labs Ltd. has published a notice to its equity shareholders regarding unclaimed equity shares from the fiscal year 2018-19. These shares are due for transfer to the Investor Education and Protection Fund (IEPF) as per Section 124(6) of the Companies Act, 2013.
The company has also sent individual notices and letters to the concerned shareholders via post to their last known addresses. Details of these shareholders are available on the company's website, www.lalpathlabs.com. The advertisement regarding this notice was published in the Financial Express and Jansatta newspapers on March 19, 2026.
What to do with a filing like this
Dr. Lal Path Labs Ltd. filed this with the NSE as a statutory disclosure, categorised under other regulatory filings. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Dr. Lal Path Labs Ltd.. Read the original for the full detail.